Benzinga | Jun 14, 2021 09:45AM EDT

Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $331

Truist Securities analyst Robyn Karnauskas maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $305 to $331.